Anti-C1q is a novel biomarker with demonstrated utility in assessing renal activity and SLE disease activity. Studies demonstrate anti-C1q may be helpful in identifying the 45% to 61% of SLE patients with renal involvement.

Anti-Phosphatidylserine/Prothrombin (PS/PT) IgM & IgG represent a breakthrough in assessing a patient’s risk of thrombosis and pregnancy loss associated with antiphospholipid syndrome (APS). In addition, PS/PT has been found to correlate with lupus anticoagulant (LAC) positivity better than other aPL methods regardless of anticoagulant treatment.

Antibodies against ribosomal proteins (Ribo P) are highly specific for SLE and can be present in anti-dsDNA or anti-Sm negative patients. Association with neuropsychiatric SLE has also been observed.

Antibodies to cardiolipin are present in SLE patients (30-40%) and APS. Prevalence of anti-cardiolipin in APS is high but specificity for APS is lower than other anti-phospholipids antibodies. Antibodies to cardiolipin IgA are less prevalent than IgG or IgM but can occur in isolation. Positive results should be confirmed after 12 weeks.

Antibodies to Beta 2 Glycoprotein 1 (β2 GP1) show higher specificity than anti-cardiolipin assays. In 3-10% of APS patients, β2 GP1 antibody may be the only positive test. Antibodies to Beta 2 Glycoprotein 1 (β2 GP1) IgA are less prevalent than IgG or IgM but can occur in isolation. Positive results should be confirmed after 12 weeks.

*Note these markers are included and reported with AVISE CTD and will not be repeated when ordered with AVISE CTD